Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T E Witzig

Showing results (101-110 of 183) with videos related to

Pageof 19
Sort By:
Cancer Genetics and Cytogenetics|June 1, 1997
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemiaA Tefferi, B J Bartholmai, T E Witzig, et al.
Hematologic Pathology|January 1, 1991
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling indexP Beauregard, T E Witzig, P J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group studyJ H Donohue, S Williams, S Cha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphomaS M Ansell, T M Habermann, P J Kurtin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphomaT E Witzig, G S Nowakowski, T M Habermann, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
Cancer|August 15, 1993
Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factorsT M Pisansky, J N Ingle, D J Schaid, et al.
Leukemia Research|January 1, 1988
Oncogene expression in T-cell lymphoproliferative disordersG E Woloschak, W C Hooper, M J Doerge, et al.
American Journal of Clinical Pathology|September 1, 1990
Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section methodT E Witzig, P M Banks, M J Stenson, et al.
Leukemia|August 28, 2013
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapyT E Witzig, G Hu, S M Offer, et al.
Pageof 19

Showing results (101-110 of 183) with videos related to

Sort By:
Pageof 19
Cancer Genetics and Cytogenetics|June 1, 1997
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemiaA Tefferi, B J Bartholmai, T E Witzig, et al.
Hematologic Pathology|January 1, 1991
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling indexP Beauregard, T E Witzig, P J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group studyJ H Donohue, S Williams, S Cha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphomaS M Ansell, T M Habermann, P J Kurtin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphomaT E Witzig, G S Nowakowski, T M Habermann, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
Cancer|August 15, 1993
Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factorsT M Pisansky, J N Ingle, D J Schaid, et al.
Leukemia Research|January 1, 1988
Oncogene expression in T-cell lymphoproliferative disordersG E Woloschak, W C Hooper, M J Doerge, et al.
American Journal of Clinical Pathology|September 1, 1990
Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section methodT E Witzig, P M Banks, M J Stenson, et al.
Leukemia|August 28, 2013
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapyT E Witzig, G Hu, S M Offer, et al.
Pageof 19